Trial Profile
Phase 1b Study to Evaluate QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Zuretinol acetate (Primary)
- Indications Leber congenital amaurosis; Retinitis pigmentosa
- Focus Therapeutic Use
- Sponsors QLT
- 27 Nov 2013 New trial record